Results of the Phase 2B Part of Time Study Evaluating TG4010 Immunotherapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy


Elisabeth Quoix, et al.
ASCO Annual Meeting 2015 – May 29-June 2, 2015 – Chicago, Illinois
Download the poster here
Poster Presentation

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00 - Fax. : + 33 (0) 3 88 27 91 11

 

© 2018 Transgene - All rights reserved
Mentions légales - Crédits